Business Wire

PATHOQUEST

23.1.2020 14:02:09 CET | Business Wire | Press release

Share
PathoQuest’s Paris-based Facility Obtains GLP Certificate for the Company’s Biologics Genomic Quality Control Testing Service

PathoQuest, a company with expertise in genomic analysis, announced today that it has received GLP certificate of conformity following a successful inspection by the French National Agency for Medicine and Health Products Safety (ANSM). PathoQuest is the first company in France to have a facility receive such a GLP certificate from the ANSM for advanced, Next Generation Sequencing viral safety testing (“high-throughput sequencing detection of incidental replicative virus test in eukaryote cells ”).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200123005345/en/

Violaine Melen, PathoQuest’s Chief of Quality Assurance and Regulatory Affairs, stated “we are really proud of the achievement of this key regulatory milestone. Receiving this GLP certificate is the confirmation of the quality of our entire process, from receipt of a biological sample to report generation, inclusive of bioinformatics analysis and data archiving. Our processes have been validated in accordance with highly recognized validation methods and computer systems guidelines such as ICHQ2(R1), IEC 62304, 21 CRF part 11, OECD annex 17.”

Next generation sequencing-based technology for biologics testing is intended to supplement or replace traditional in-vivo or in-vitro testing methods in order to support more rapid and robust decision-making as a part of the QC process. Jean-François Brepson, PathoQuest’s CEO, commented “Thanks to efficient teamwork, PathoQuest is now able to offer GLP-certified viral safety testing based on our proprietary NGS approach. This certification provides the company with a significant new market opportunity in addition to the current testing we perform in a R&D environment. Our innovative QC process is particularly adapted to biotech and biopharma companies developing Advanced Therapy Medicinal Products (ATMPs), vaccines and other biologicals .”

About PathoQuest

PathoQuest offers biopharmaceutical companies a game changing Genomic approach to secure the biosafety of biological drugs like cell & gene therapy products, vaccines and recombinant. It allows to reduce time to market of innovative treatments.

PathoQuest’s technology combines a Next-Generation Sequencing (NGS) platform with a proprietary sample preparation processes completed by a proprietary pathogen genome sequence databases and automated analysis pipeline.

PathoQuest has signed in 2018 a strategic partnership with Charles River Lab (Boston, USA).

Based on its technological platform, PathoQuest has also developed a metagenomic test direct from blood (iDTECT®) to improve the diagnosis of Bloodstream infections and fight against Antimicrobial Resistance (AMR)

For more information about PathoQuest, visit www.pathoquest.com or contact us at welcome@pathoquest.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

TreviPay Partners with Dynatos to Add e-Invoicing Capabilities to its B2B Payments Infrastructure15.9.2026 07:00:00 CEST | Press release

The partnership brings e-invoicing technology and compliance expertise into TreviPay’s B2B payments infrastructure as requirements expand across Europe and other markets TreviPay, a global B2B payments infrastructure partner, today announced a partnership with Dynatos to expand e-invoicing capabilities for TreviPay clients operating across Europe and other markets. Through the partnership, Dynatos Routty Cloud proposition will provide embedded e-invoicing technology and compliance support, helping TreviPay clients exchange invoices across different formats, networks and country requirements in Europe and other global markets. E-invoicing requirements continue to expand across Europe and other global markets, adding complexity for businesses managing invoices across more than 60 countries with mandates announced or already in place. At the same time, invoicing has become an increasingly important part of the B2B buyer experience. TreviPay research found 68% of B2B buyers are more likely

Meiji Group to Showcase Japanese-Quality CMO/CDMO Services and a Global Manufacturing Network at CPHI Milan 202615.9.2026 07:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (HQ: Chuo-ku, Tokyo; President and CEO: Toshiaki Nagasato) will debut as the Meiji Group’s Pharmaceutical Segment at CPHI Milan 2026, at Fiera Milano, Milan, Italy, October 6–8, 2026. At the exhibition, the Meiji Group’s Pharmaceuticals Segment will showcase 80 years of expertise in Japanese standard quality control, manufacturing, and supply network from Japan to Europe, India, and Southeast Asia. It will also highlight group-wide contract manufacturing, from development to supply, tailored to customer needs. Through the exhibition, Meiji Seika Pharma aims to raise global awareness of the Meiji Group’s Pharmaceutical Segment, its brands, capabilities, production capacity, and contract manufacturing services, and to forge new global partnerships to expand its CMO/CDMO business. “CPHI Milan 2026” Exhibition Overview Exhibition Name: CPHI Milan 2026 Dates: October 6 (Tue) – 8 (Thu), 2026 Venue: Fiera Milano (Milan, Italy) Exhibition Area: CMO Area Booth Numbe

Signaloid joins Open Chiplet Atlas Alliance andAnnounces Plans to Make Its UxHw ASICs Available via OCA Ecosystem15.9.2026 06:00:00 CEST | Press release

British compute hardware company Signaloid joins Open Chiplet Atlas (OCA) and plans to bring its distribution-extended compute hardware (UxHw) compute acceleration technology to the OCA ecosystem.UxHw technology speeds up compute-intensive stochastic workloads in AI, science and engineering simulations, robotics, and quantitative finance. British compute hardware company Signaloid has joined the Open Chiplet Atlas (OCA) and announced plans to make its UxHw® compute acceleration technology available as chiplets within the OCA ecosystem. The UxHw technology targets AI and simulation workloads that rely on stochastic methods, including quantitative finance, reinforcement learning, engineering simulations, and world models. The announcement follows Signaloid’s recent tapeout of a UxHw ASIC for robotics and physical AI in an ultra-low-power TSMC process. “The Open Chiplet Atlas (OCA) increases innovation in chip design by defining an open architecture for multi-vendor chiplet interoperabili

Rimini Street and Datacom Announce Strategic Partnership to Accelerate AI Adoption and Drive IT Optimisation Across ANZ14.9.2026 22:00:00 CEST | Press release

Collaboration delivers expert third-party support for Oracle and SAP, keeping systems secure, compliant and stable for immediate Agentic AI ERP innovation while freeing up capital for growth and profitability Rimini Street Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle and SAP software, today announced a strategic partnership with Datacom, one of Australasia’s largest homegrown technology services and solutions providers. The reseller agreement will see Datacom offer Rimini Support™ for Oracle and SAP software to its public and private sector customers across Australia and New Zealand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914070894/en/ Rimini Street and Datacom Announce Strategic Partnership to Accelerate AI Adoption and Drive IT Optimisation Across ANZ This collaboration brings together Rimini Street's third-party software support, t

Lattice to Showcase Next Gen Automotive Sensing Innovations at AutoSens Europe 202614.9.2026 22:00:00 CEST | Press release

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced its exhibition plan for the upcoming AutoSens Europe 2026, taking place on Sept. 22 – 24, 2026, in Barcelona, Spain. As part of the event, Lattice will deliver a technical presentation and host a demo showcase focused on how its low power FPGA solutions are enabling next-generation automotive sensing, ADAS, and in-vehicle networking applications. Who: Lattice Semiconductor What / When (GMT+2): Sept. 22 – 24, 2026 Lattice Demo Showcase at Booth #215 from local dimming, camera monitoring system, sensor security, and more. Presentation (Sept. 23 at 2:30 p.m., Room 5) “Efficient 360° threat detection for parked vehicles – A distributed, event-driven approach” Where: La Farga de L’Hospitalet, Barcelona, Spain AutoSens Europe is the automotive industry's premier conference and exhibition for perception systems, ADAS, and autonomous vehicle technology. Bringing together over 1,000 en

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye